CRBP · Corbus Pharmaceuticals Holdings, Inc.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.

This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.33 to $7.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 58,300 unvested RSUs subject to the grant's vesting schedule as previously reported.

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on May 21, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on June 21, 2027.

On May 21, 2026, the Reporting Person was granted 58,300 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth annual anniversary beginning on May 21, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

This amount includes 58,300 unvested RSUs granted on May 21, 2026.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

On May 19, 2026, 7,500 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

This amount includes 7,500 unvested RSUs that were granted on May 19, 2026 and will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to continued service to the Company through each applicable vesting date.

On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.20 to $8.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 73,765 unvested RSUs subject to each grant's vesting schedule as previously reported.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 46,362 unvested RSUs subject to each grant's vesting schedule as previously reported.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 68,795 unvested RSUs subject to each grant's vesting schedule as previously reported.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 and the sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 48,108 unvested RSUs subject to each grant's vesting schedule as previously reported.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.01 to $8.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 86,265 unvested RSUs subject to each grant's vesting schedule as previously reported.

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

On January 14, 2026, the Reporting Person was granted 28,365 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

This amount includes 53,108 unvested RSUs subject to each grant's vesting schedule as previously reported.

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

On January 14, 2026, the Reporting Person was granted 28,365 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

This amount includes 93,065 unvested RSUs subject to each grant's vesting schedule as previously reported.

On January 14, 2026, the Reporting Person was granted 28,082 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

This amount includes 85,714 unvested RSUs subject to each grant's vesting schedule as previously reported.

On January 14, 2026, the Reporting Person was granted 50,000 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a prorata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

This amount includes 173,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

The reported price represents the weighted average sale price of Common Stock (the "shares") sold in a series of open market transactions on the transaction date at prices ranging from $11.20 to $12.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund.

Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.

The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.

This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.

This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2024.

This amount includes 4,800 unvested RSUs that were granted on May 30, 2025 and vest 100% on the one-year anniversary of the date of grant.

The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.

On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 10,366 unvested RSUs subject to each grant's vesting schedule as previously reported.

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.